Comprehensive Analysis of N6-Methylandenosine-Related lncRNAs in Clear Cell Renal Cell Carcinoma: A Correlation With Prognosis, Tumor Progression, and Therapeutic Response

References

• Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2022;72(5):409–436. doi:10.3322/caac.21731.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349(nov10 11):g4797–g4797. doi:10.1136/bmj.g4797.
   PubMed Web of Science ®Google Scholar
• Ferro M, Crocetto F, Barone B, Del Giudice F, Maggi M, Lucarelli G, et al. Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review. Ther Adv Urol. 2023;15:17562872231164803. doi:10.1177/17562872231164803.
   Web of Science ®Google Scholar
• Ferro M, Musi G, Marchioni M, Maggi M, Veccia A, Del Giudice F, et al. Radiogenomics in renal cancer management-current evidence and future prospects. Int J Mol Sci. 2023;24(5):4615. doi:10.3390/ijms24054615.
   PubMed Web of Science ®Google Scholar
• Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13(8):496–511. doi:10.1038/nrneph.2017.82.
   PubMed Web of Science ®Google Scholar
• Napolitano L, Manfredi C, Cirillo L, Fusco GM, Passaro F, Abate M, et al. Cytoreductive nephrectomy and metastatic renal cell carcinoma: state of the art and future perspectives. Medicina. 2023;59(4):767. doi:10.3390/medicina59040767.
   PubMedGoogle Scholar
• Gill DM, Hahn AW, Hale P, et al. Overview of current and future first-line systemic therapy for metastatic clear cell renal cell carcinoma. Curr Treat Options Oncol. 2018;19:6.
   PubMed Web of Science ®Google Scholar
• Wan B, Liu B, Yu G, Huang Y, Lv C. Differentially expressed autophagy-related genes are potential prognostic and diagnostic biomarkers in clear-cell renal cell carcinoma. Aging. 2019;11(20):9025–9042. doi:10.18632/aging.102368.
   PubMedGoogle Scholar
• Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613. doi:10.1016/j.biopha.2019.108613.
   PubMed Web of Science ®Google Scholar
• Liu Z-X, Li L-M, Sun H-L, Liu S-M. Link between m6A modification and cancers. Front Bioeng Biotechnol. 2018;6:89. doi:10.3389/fbioe.2018.00089.
   PubMed Web of Science ®Google Scholar
• Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608–624. doi:10.1038/s41580-019-0168-5.
   PubMed Web of Science ®Google Scholar
• Li X, Tang J, Huang W, Wang F, Li P, Qin C, et al. The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma. Oncotarget. 2017;8(56):96103–96116. doi:10.18632/oncotarget.21726.
   PubMedGoogle Scholar
• Gu Y, Niu S, Wang Y, Duan L, Pan Y, Tong Z, et al. DMDRMR-mediated regulation of (m)(6)A-modified CDK4 by m(6)A reader IGF2BP3 drives ccRCC progression. Cancer Res. 2021;81(4):923–934. doi:10.1158/0008-5472.CAN-20-1619.
   PubMed Web of Science ®Google Scholar
• Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62. doi:10.1038/nrg.2015.10.
   PubMed Web of Science ®Google Scholar
• Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015. doi:10.3390/cells8091015.
   PubMed Web of Science ®Google Scholar
• Xie J, Zhong Y, Chen R, Li G, Luo Y, Yang J, et al. Serum long non-coding RNA LINC00887 as a potential biomarker for diagnosis of renal cell carcinoma. FEBS Open Bio. 2020;10(9):1802–1809. doi:10.1002/2211-5463.12930.
   PubMed Web of Science ®Google Scholar
• He ZH, Qin XH, Zhang XL, et al. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2018;22:46.
   PubMedGoogle Scholar
• Qu L, Ding J, Chen C, Wu Z-J, Liu B, Gao Y, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653–668. doi:10.1016/j.ccell.2016.03.004.
   PubMed Web of Science ®Google Scholar
• Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wøjdemann M, Johansen JS, et al. Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer–five microRNAs in a prognostic index. World J Surg. 2012;36(11):2699–2707. doi:10.1007/s00268-012-1705-y.
   PubMed Web of Science ®Google Scholar
• Han Z, Wang H, Liu Y, Xing X-L. Establishment of a prognostic ferroptosis- and immune-related long noncoding RNAs profile in kidney renal clear cell carcinoma. Front Genet. 2022;13:915372. doi:10.3389/fgene.2022.915372.
   PubMed Web of Science ®Google Scholar
• Li X, Kuang Q, Peng M, Yang K, Luo P. Basement membrane-associated lncRNA risk model predicts prognosis and guides clinical treatment in clear cell renal cell carcinoma. Biomedicines. 2023;11(10):2635. doi:10.3390/biomedicines11102635.
   PubMed Web of Science ®Google Scholar
• Shen J, Wang L, Bi J. Bioinformatics analysis and experimental validation of cuproptosis-related lncRNA LINC02154 in clear cell renal cell carcinoma. BMC Cancer. 2023;21:160.
   Google Scholar
• Yu JJie, mao WPu, Sun S, Hu Q, Wang C, Xu Z, et al. Identification of an m6A-related lncRNA signature for predicting the prognosis in patients with kidney renal clear cell carcinoma. Front Oncol. 2021;11:663263. doi:10.3389/fonc.2021.663263.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhuang M, Tu X-H, Li C-C, Liu H-H, Wang J, et al. Bioinformatics analysis of markers based on m(6) A related to prognosis combined with immune invasion of renal clear cell carcinoma. Cell Biol Int. 2023;47(1):260–272. doi:10.1002/cbin.11929.
   PubMed Web of Science ®Google Scholar
• Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res. 2021;27(5):1236–1241. doi:10.1158/1078-0432.CCR-20-3054.
   PubMed Web of Science ®Google Scholar
• Fumet J-D, Truntzer C, Yarchoan M, Ghiringhelli F. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer. 2020;131:40–50. doi:10.1016/j.ejca.2020.02.038.
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–672. doi:10.1016/j.annonc.2021.02.006.
   PubMed Web of Science ®Google Scholar
• Yue H, Wu K, Liu K, Gou L, Huang A, Tang H, et al. LINC02154 promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing SPC24 promoter activity and activating the PI3K-AKT signaling pathway. Cell Oncol. 2022;45(3):447–462. doi:10.1007/s13402-022-00676-7.
   Web of Science ®Google Scholar
• Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T, et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518(7540):560–564. doi:10.1038/nature14234.
   PubMed Web of Science ®Google Scholar
• Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, et al. m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12(1):135. doi:10.1186/s13045-019-0830-6.
   PubMed Web of Science ®Google Scholar
• Zheng Z-Q, Li Z-X, Zhou G-Q, Lin L, Zhang L-L, Lv J-W, et al. Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3. Cancer Res. 2019;79(18):4612–4626. doi:10.1158/0008-5472.CAN-19-0799.
   PubMed Web of Science ®Google Scholar
• Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J, et al. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol. 2020;13(1):5. doi:10.1186/s13045-019-0839-x.
   PubMed Web of Science ®Google Scholar
• Shen J, Feng X-P, Hu R-B, Wang H, Wang Y-L, Qian J-H, et al. N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma. Lab Invest. 2021;101(6):775–784. doi:10.1038/s41374-021-00543-3.
   PubMed Web of Science ®Google Scholar
• Sun T, Wu Z, Wang X, Wang Y, Hu X, Qin W, et al. LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020;39(31):5358–5372. doi:10.1038/s41388-020-1338-9.
   PubMed Web of Science ®Google Scholar
• Zhu X, Tian X, Yu C, Shen C, Yan T, Hong J, et al. A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Mol Cancer. 2016;15(1):60. doi:10.1186/s12943-016-0544-0.
   PubMed Web of Science ®Google Scholar
• Tu Z, Wu L, Wang P, Hu Q, Tao C, Li K, et al. N6-methylandenosine-related lncRNAs are potential biomarkers for predicting the overall survival of lower-grade glioma patients. Front Cell Dev Biol. 2020;8:642. doi:10.3389/fcell.2020.00642.
   PubMed Web of Science ®Google Scholar
• Xu F, Huang X, Li Y, Chen Y, Lin L. m(6)A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mol Ther Nucleic Acids. 2021;24:780–791. doi:10.1016/j.omtn.2021.04.003.
   PubMedGoogle Scholar
• Wang J-M, Li X, Yang P, Geng W-B, Wang X-Y. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients. BMC Gastroenterol. 2022;22(1):76. doi:10.1186/s12876-022-02159-3.
   PubMed Web of Science ®Google Scholar
• Zhou W, Zhao Q, Sutton R, Cumming H, Wang X, Cerruti L, et al. The role of p22 NF-E4 in human globin gene switching. J Biol Chem. 2004;279(25):26227–26232. doi:10.1074/jbc.M402191200.
   PubMed Web of Science ®Google Scholar
• Pan Q, Wang L, Zhang H, Liang C, Li B. Identification of a 5-gene signature predicting progression and prognosis of clear cell renal cell carcinoma. Med Sci Monit. 2019;25:4401–4413. doi:10.12659/MSM.917399.
   PubMed Web of Science ®Google Scholar
• Zhu Y, He J, Li Z, Yang W. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia. BMC Bioinformatics. 2023;24(1):37. doi:10.1186/s12859-023-05148-9.
   PubMed Web of Science ®Google Scholar
• Cao H, Tong H, Zhu J, Xie C, Qin Z, Li T, et al. A glycolysis-based long non-coding RNA signature accurately predicts prognosis in renal carcinoma patients. Front Genet. 2021;12:638980. doi:10.3389/fgene.2021.638980.
   PubMedGoogle Scholar
• Zhang Y, Zhuang T, Xin Z, Sun C, Li D, Ma N, et al. Construction of a necroptosis-related lncRNA signature for predicting prognosis and immune response in kidney renal clear cell carcinoma. Cells. 2022;12(1):66. doi:10.3390/cells12010066.
   PubMed Web of Science ®Google Scholar
• Lai J, Miao S, Ran L. Ferroptosis-associated lncRNA prognostic signature predicts prognosis and immune response in clear cell renal cell carcinoma. Sci Rep. 2023;13(1):2114. doi:10.1038/s41598-023-29305-5.
   PubMedGoogle Scholar
• Jiang P, Xue W, Xi C, Zhuang L, Yuan Z, Liu Z, et al. A new acidic microenvironment related lncRNA signature predicts the prognosis of liver cancer patients. Front Oncol. 2022;12:1016721. doi:10.3389/fonc.2022.1016721.
   PubMedGoogle Scholar
• Wang X, Pan Y, Ou Y, Duan T, Zou Y, Zhou X, et al. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma. World J Surg Oncol. 2022;20(1):164. doi:10.1186/s12957-022-02608-z.
   PubMed Web of Science ®Google Scholar
• Gong S, Xu M, Zhang Y, Shan Y, Zhang H. The prognostic signature and potential target genes of six long non-coding RNA in laryngeal squamous cell carcinoma. Front Genet. 2020;11:413. doi:10.3389/fgene.2020.00413.
   PubMed Web of Science ®Google Scholar
• Qian L, Ni T, Fei B, Sun H, Ni H. An immune-related lncRNA pairs signature to identify the prognosis and predict the immune landscape of laryngeal squamous cell carcinoma. BMC Cancer. 2022;22(1):545. doi:10.1186/s12885-022-09524-1.
   PubMed Web of Science ®Google Scholar
• Zhang G, Fan E, Zhong Q, Feng G, Shuai Y, Wu M, et al. Identification and potential mechanisms of a 4-lncRNA signature that predicts prognosis in patients with laryngeal cancer. Hum Genomics. 2019;13(1):36. doi:10.1186/s40246-019-0230-6.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104. doi:10.1056/NEJMoa1801946.
   PubMed Web of Science ®Google Scholar
• Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36(17):1685–1694. doi:10.1200/JCO.2017.75.7740.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33(5):843.e4–852.e4. doi:10.1016/j.ccell.2018.03.018.
   Web of Science ®Google Scholar
• Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633–641. doi:10.1200/JCO.2017.75.3384.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi:10.1056/NEJMc1713444.
   PubMed Web of Science ®Google Scholar
• Labriola MK, Zhu J, Gupta RT, McCall S, Jackson J, Kong EF, et al. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000319. doi:10.1136/jitc-2019-000319.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar